29 August 2016, Moscow
In August 2016, NPO Petrovax Pharm delivered 1.5 m doses of its Grippol® Plus anti-influenza vaccine to the Republic of Kazakhstan. The shipments were made under the government's procurement programme providing for the purchase of medicines and healthcare products from the SK-Pharmacy's uniform distributor in the scope of the guaranteed free medical care plan.
In the 2016–2017 epidemiological season, all people of Kazakhstan subject to free mandatory vaccination (including children from six months of age, pregnant women, healthcare personnel, people aged 60 and over) will for the first time be vaccinated with Grippol® Plus.
Elena Arkhangelskaya, President of NPO Petrovax Pharm, noted that the new export deal was another testament to the Russian vaccine’s high efficacy, safety and quality. “Kazakhstan’s pharmaceutical market is one of the most dynamic and fast-growing international markets, and it presents a great platform for fostering cooperation. This export agreement demonstrates the strengths of Russia’s immunobiological industry and the global demand for its products. It is also another step toward bolstering cooperation within the pharmaceutical industry among the Eurasian Economic Union (EAEU) member countries,” said Arkhangelskaya.
Kazakhstan’s current population is over 17 million people1, 9% of whom will receive free vaccinations under a government programme. NPO Petrovax Pharm has been operating in the Kazakhstan market since 2006 and has built a reputation of a reliable exporter with a portfolio full of sought-after high-quality medicines.
As a result of NPO Petrovax Pharm’s active efforts to build up its export business, the Company currently exports immunobiological medicines to 11 countries. With Grippol® and Grippol® Plus developed by Petrovax Pharm and extensively used in Russia and EurAsEC countries for over 20 years, the Company is successfully competing in international markets.
According to Euromonitor2, primary pharmaceuticals exports from Russia to Kazakhstan are continuously growing. Kazakhstan is Russia’s key export partner (20% of the total pharmaceutical exports in 2014–2015)3.